Drug firm Zydus Cadila receives an approval from Mexico's regulatory authority Cofepris to conduct clinical trials in the Latin American country with its biological therapy "Pegylated Interferon alpha-2b" for treatment of Covid-19. Clinical and regulatory development of the therapy in Covid-19 is being executed in Mexico by Avant Sant Research Center S.A. de C.V., a contract research organisation (CRO) headquartered in Monterrey, Mexico.
Drug firm Zydus Cadila receives an approval from Mexico's regulatory authority Cofepris to conduct clinical trials in the Latin American country with its biological therapy "Pegylated Interferon alpha-2b" for treatment of Covid-19. Clinical and regulatory development of the therapy in Covid-19 is being executed in Mexico by Avant Sant Research Center S.A. de C.V., a contract research organisation (CRO) headquartered in Monterrey, Mexico.
139.jpeg)
260.jpeg)
259.jpeg)
258.jpeg)
